Who is sponsoring NCT04751409?

NCT04751409 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT04751409?

Interventions in NCT04751409: Chest Radiography, Computed Tomography, Follow-Up, Follow-Up, Imaging Technique, Questionnaire Administration.

What condition does NCT04751409 study?

NCT04751409 studies Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8.

Is NCT04751409 still recruiting?

NCT04751409 is currently recruiting now. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT04751409

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Recruiting now Phase 2 Last updated 5 March 2026

What this trial tests

Phase 2 trial testing Chest Radiography in Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 in 227 participants. Currently enrolling.

Timeline

28 December 2020

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	227
Start date	28 December 2020
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Chest Radiography
Computed Tomography
Follow-Up
Follow-Up
Imaging Technique
Questionnaire Administration

Conditions studied

Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 — all drugs for Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 →
Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 — all drugs for Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 →
Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 — all drugs for Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 →
Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 — all drugs for Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 or Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how anxiety is affected by 2 types of follow-up after surgery, limited follow-up and intense follow-up, in patients with stage II-III soft tissue sarcoma of the trunk and extremities. In cancer survivors, the fear of cancer coming back (recurring) is common and may persist long after the end of treatment. It may also be exacerbated by return visits for imaging (surveillance). The purpose of this study is to determine how patients' anxiety and other cancer-related outcomes are affected by how often surveillance is done.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma.
Whitaker J, Nessim C, Almond M, Ford SJ. · · 2023 · cited 6× · PMID 36975424 · DOI 10.3390/curroncol30030211

Verify or expand the search:

Other trials of Chest Radiography

Trials testing the same drug.

NCT06954987 — Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell · Phase 2 · not yet recruiting
NCT07225985 — Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re · Phase 1, PHASE2 · not yet recruiting
NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C · Phase 3 · recruiting
NCT06928662 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant · Phase 1, PHASE2 · recruiting

Other recruiting trials for Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Currently open trials in the same condition.

NCT04562480 — Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk · Phase 2 · active not recruiting
NCT04420975 — Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma · Phase 1 · active not recruiting
NCT03819985 — Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tiss · Phase 2 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04751409 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04751409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing